1. Figure 5 Drugs that target WNT signalling
Figure 5 | Drugs that target WNT signalling. Many drugs have been developed that act on different targets at different levels in the WNT signalling pathway. The therapeutics are inhibitors of WNT secretion (red), regulators of WNT antagonist and antagonist function (blue), drugs that target WNT receptor interactions (green), drugs that prevent dishevelled (DVL) activation (pink), drugs that stabilize the destruction complex (grey), and drugs that target β-catenin (β-cat) partners in the nucleus (purple). APC, adenomatous polyposis coli protein; CBP, CREB-binding protein; CK1, casein kinase 1; DKK, Dickkopf-related protein; FZD, frizzled; GSK, glycogen synthase kinase; LRG, leucine-rich repeat-containing G protein-coupled receptor; LRP, low-density lipoprotein receptor; sFRP, secreted frizzled-related protein; TCF, T-cell factor; TAZ, transcriptional co-activator with PDZ-binding motif; ROR, tyrosine protein kinase transmembrane receptor; WLS, wntless homologue; YAP, yes-associated protein.
Murillo-Garzón, V. & Kypta, R. (2017) WNT signalling in prostate cancer
Nat. Rev. Urol. doi: /nrurol